Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial

OBJECTIVES: To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days), versus oseltamivir (75 mg orally twice a day for 5 days), and versus Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alon...

Descripción completa

Detalles Bibliográficos
Autores principales: Akram, Javed, Azhar, Shehnoor, Shahzad, Muhammad, Latif, Waqas, Khan, Khalid Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414257/
https://www.ncbi.nlm.nih.gov/pubmed/32771032
http://dx.doi.org/10.1186/s13063-020-04616-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414257/
https://www.ncbi.nlm.nih.gov/pubmed/32771032
http://dx.doi.org/10.1186/s13063-020-04616-4

Ejemplares similares